Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
Top Cited Papers
Open Access
- 20 March 2013
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 309 (11), 1154-1162
- https://doi.org/10.1001/jama.2013.2194
Abstract
Severe sepsis, a syndrome of acute infection complicated by organ dysfunction, is caused by a dysregulated systemic inflammatory response. Sepsis can progress to systemic hypotension (septic shock), manifest by hypoperfusion of vital organs, multiple organ dysfunction, and death.1-3Keywords
This publication has 22 references indexed in Scilit:
- Nationwide Trends of Severe Sepsis in the 21st Century (2000–2007)Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2011
- Immunotherapy for Sepsis — A New Approach against an Ancient FoeThe New England Journal of Medicine, 2010
- The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsisIntensive Care Medicine, 2010
- Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003*Critical Care Medicine, 2007
- Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004
- Diagnostic and Prognostic Implications of Endotoxemia in Critical Illness: Results of the MEDIC StudyThe Journal of Infectious Diseases, 2004
- Inhibition of Endotoxin Response by E5564, a Novel Toll-Like Receptor 4-Directed Endotoxin AntagonistThe Journal of pharmacology and experimental therapeutics, 2002
- Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of careCritical Care Medicine, 2001
- Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic ShockThe Journal of Infectious Diseases, 1999
- MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4The Journal of Experimental Medicine, 1999